A recent study from the Mayo Clinic reveals that postmenopausal women undergoing hormone therapy experience significantly more weight loss when treated with semaglutide, a popular anti-obesity drug, compared to those not on hormone therapy. The study found that women on hormone therapy lost approximately 30% more weight, with an average of 16% total body weight loss over 12 months, aligning with results seen in broader clinical trials.
The research, though preliminary, suggests that menopause itself may reduce the effectiveness of semaglutide in women who do not receive hormone therapy. Hormone therapy might help maintain a more typical response to the drug, possibly due to its effects on body composition and mitigation of menopausal symptoms that could otherwise hinder weight loss efforts.
This finding is particularly relevant as weight gain during menopause is common, affecting nearly 70% of women, and can increase the risk of cardiometabolic diseases. The study highlights the potential benefits of hormone therapy in enhancing the effectiveness of weight loss options like semaglutide, though further research is needed to fully understand the mechanisms at play.
For women considering hormone therapy, this study adds another layer to the conversation, especially as demand for anti-obesity medications rises among the menopausal demographic. As hormone therapy appears to be gaining popularity again, these insights could influence care decisions for women seeking to manage their weight during menopause.
If you’d like to know more about hormone therapy or learn about medical weight management options, call Liquid Mobile today at 855-954-7843.